Evidence map›Paper›PMID 35426241›Full record

ArticleZoonoses and public health2022

Transmission of SARS-CoV-2 Delta variant (B.1.617.2) from a fully vaccinated human to a canine in Georgia, July 2021.

Natalie M Wendling, Ann Carpenter, Amanda Liew, Ria R Ghai, Nadia Gallardo-Romero, Robyn A Stoddard, Ying Tao, Jing Zhang, Adam C Retchless, Ausaf Ahmad and 13 more

Abstract read
In one paragraph

Article in Zoonoses and public health, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Natalie M WendlingCenters for Disease Control and Prevention, Atlanta, Georgia, USA.ORCID 0000-0002-5738-2738
Ann CarpenterCenters for Disease Control and Prevention, Atlanta, Georgia, USA.ORCID 0000-0003-0118-2726
Amanda LiewCenters for Disease Control and Prevention, Atlanta, Georgia, USA.ORCID 0000-0001-6984-1797
Ria R GhaiCenters for Disease Control and Prevention, Atlanta, Georgia, USA.
Nadia Gallardo-RomeroCenters for Disease Control and Prevention, Atlanta, Georgia, USA.
Robyn A StoddardCenters for Disease Control and Prevention, Atlanta, Georgia, USA.
Ying TaoCenters for Disease Control and Prevention, Atlanta, Georgia, USA.
Jing ZhangCenters for Disease Control and Prevention, Atlanta, Georgia, USA.
Adam C RetchlessCenters for Disease Control and Prevention, Atlanta, Georgia, USA.
Ausaf AhmadCenters for Disease Control and Prevention, Atlanta, Georgia, USA.
Paige BunkleyCenters for Disease Control and Prevention, Atlanta, Georgia, USA.
Claire GodinoCenters for Disease Control and Prevention, Atlanta, Georgia, USA.
Matthew R MauldinCenters for Disease Control and Prevention, Atlanta, Georgia, USA.
Kate VarelaCenters for Disease Control and Prevention, Atlanta, Georgia, USA.ORCID 0000-0002-3885-4496
Jana M RitterCenters for Disease Control and Prevention, Atlanta, Georgia, USA.
Janemarie HennebelleGeorgia Department of Agriculture, Atlanta, Georgia, USA.
Amanda FeldpauschGeorgia Department of Public Health, Atlanta, Georgia, USA.
Julie GabelGeorgia Department of Public Health, Atlanta, Georgia, USA.
Markus H KainulainenCenters for Disease Control and Prevention, Atlanta, Georgia, USA.
Owen HerzeghCenters for Disease Control and Prevention, Atlanta, Georgia, USA.
Suxiang TongCenters for Disease Control and Prevention, Atlanta, Georgia, USA.
Jessica R SpenglerCenters for Disease Control and Prevention, Atlanta, Georgia, USA.ORCID 0000-0002-5383-0513
Casey Barton BehraveshCenters for Disease Control and Prevention, Atlanta, Georgia, USA.ORCID 0000-0003-2270-5573

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

SARS-CoV-2 infection has been described in a wide range of species, including domestic animals such as dogs and cats. Illness in dogs is usually self-limiting, and further diagnostics may not be pursued if clinical signs resolve or they respond to empirical treatment. As new variants emerge, the clinical presentation and role in transmission may vary in animals. This report highlights different clinical presentations and immunological responses in two SARS-CoV-2 Delta-variant-positive dogs with similar exposure to the same fully vaccinated human with a SARS-CoV-2 infection and emphasizes the need for active surveillance and additional One Health research on SARS-CoV-2 variant infections in companion animals and other species.

Indexed as

COVID-19Dog DiseasesAnimalsAnimals, DomesticCat DiseasesCatsDogsGeorgiaHumansSARS-CoV-2companion animalCOVID-19DeltaOne HealthSARS-CoV-2

Identifiers

PMID35426241
PMCPMC9115446

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.